However, iv iron treatment in the CKD population is also often routinely provided to iron repleted individuals in order to maintain iron stores and EPO responsiveness, and as such it is of importance to study whether iv iron administration influences FGF23 and mineral homeostasis in the iron repleted condition. This evidence concerns the gene EPO and chronic kidney disease.